Standout Papers
- Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations (2018)
- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial (2017)
Immediate Impact
4 from Science/Nature 68 standout
Citing Papers
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
New promises and challenges in the treatment of advanced non-small-cell lung cancer
2024 Standout
Works of Eric Sbar being referenced
Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations
2018 Standout
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
2017 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Eric Sbar | 1032 | 1160 | 108 | 406 | 29 | 1.4k | |
| Xiuyu Julie Cong | 1211 | 1270 | 110 | 555 | 19 | 1.7k | |
| Adam Płużański | 1556 | 1636 | 100 | 459 | 55 | 2.0k | |
| Erzsébet Juhász | 1151 | 1035 | 70 | 557 | 28 | 1.7k | |
| J. A. Engelman | 822 | 1002 | 47 | 505 | 24 | 1.2k | |
| Vladimir Vladimirov | 1247 | 662 | 82 | 230 | 23 | 1.5k | |
| Chien‐Hung Gow | 740 | 1024 | 97 | 338 | 30 | 1.3k | |
| Dana Ghiorghiu | 794 | 911 | 74 | 487 | 35 | 1.3k | |
| Maria Rita Migliorino | 1559 | 1735 | 139 | 494 | 40 | 2.3k | |
| Aleksandra Markovets | 814 | 1082 | 71 | 550 | 38 | 1.3k | |
| Zhenfan Yang | 1060 | 1208 | 83 | 546 | 38 | 1.8k |
All Works
Loading papers...